P2Y12 Receptor Antagonist
Phase 3Small molecule
P2Y12 Receptor Antagonist is one of 5 small molecule programs targeting Anti-inflammatory Therapy. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Anti-Inflammatory Therapy
#DrugCompanyPhaseTrials
1Colcrys
Jazz PharmaceuticalsApproved
Bayer Aspirin
BayerApproved
Rayos
RRoxane Laboratories
Approved
P2Y12 Receptor Antagonist
FFu Wai Hospital, Beijing, China
Phase 3
Lipid-Lowering Drug
FFirst Affiliated Hospital of Wenzhou Medical University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for P2Y12 Receptor Antagonist. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- FFu Wai Hospital, Beijing, China